BRAF and melanoma: The discovery of the prevalence of BRAF mutation in this disease (≈50% of cases) and the role of the oncoprotein, particularly the highly active V600E variant, in the onset and progression of melanoma2, 3 have fuelled much interest in targeting the BRAF-MEK-ERK pathway for melanoma treatment.